Huamao Mark Lin

2.4k total citations · 1 hit paper
73 papers, 1.0k citations indexed

About

Huamao Mark Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Huamao Mark Lin has authored 73 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 47 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Huamao Mark Lin's work include Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (22 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Huamao Mark Lin is often cited by papers focused on Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (22 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Huamao Mark Lin collaborates with scholars based in United States, United Kingdom and Japan. Huamao Mark Lin's co-authors include Barbara E. Bierer, Yu Yin, Jianchang Lin, Danny Nguyen, Sylvie Vincent, Minal Mehta, Shu Jin, Mohammad Jahanzeb, Sai‐Hong Ignatius Ou and Xiaoyun Pan and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Huamao Mark Lin

72 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

2021 196 citations James Chih‐Hsin Yang, Tarek Mekhail et al. profile →

Peers

Countries citing papers authored by Huamao Mark Lin

Since Specialization

Citations

This map shows the geographic impact of Huamao Mark Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huamao Mark Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huamao Mark Lin more than expected).

Fields of papers citing papers by Huamao Mark Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huamao Mark Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huamao Mark Lin. The network helps show where Huamao Mark Lin may publish in the future.

Co-authorship network of co-authors of Huamao Mark Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Huamao Mark Lin. A scholar is included among the top collaborators of Huamao Mark Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huamao Mark Lin. Huamao Mark Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial 2025 ·Journal of Clinical Oncology ·Pasi A. Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Maximilian J. Hochmair, Solange Peters, Benjamin Besse, Nick Pavlakis, Joel W. Neal, Terufumi Kato, Yi‐Long Wu, Danny Nguyen, (unknown), Jianchang Lin, Florin Vranceanu, Annette Szumski, Huamao Mark Lin, Robert J. Fram, Tony Mok	7
2	Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database 2024 ·Journal of Thoracic Oncology ·Kaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, Aaron S. Mansfield, (unknown), (unknown), Huamao Mark Lin, Sylvie Vincent, Jennifer Elliott, (unknown)	11
3	Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial 2023 ·Journal of Thoracic Oncology ·James Chih‐Hsin Yang, Geoffrey Liu, Shun Lü, Jianxing He, Mauricio Burotto, Myung‐Ju Ahn, Dong‐Wan Kim, Xiaoqing Liu, Yanqiu Zhao, Sylvie Vincent, Jiani C. Yin, Xin Ma, Huamao Mark Lin, Sanjay Popat	28
4	Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison 2023 ·Lung Cancer ·Sai‐Hong Ignatius Ou, Huamao Mark Lin, Jin‐Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal	4
5	Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial 2023 ·Lung Cancer ·M.R. García Campelo, (unknown), Huamao Mark Lin, (unknown), Jing Shen, (unknown), D. Ross Camidge	1
6	Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations 2023 ·Lung Cancer ·Petros Christopoulos, (unknown), Jin‐Liern Hong, Huamao Mark Lin, Luis Hernández, Shu Jin, Min Tan, Irina Proskorovsky, Jianchang Lin, Pingkuan Zhang, Jyoti D. Patel, Sai‐Hong Ignatius Ou, Michael Thomas, Albrecht Stenzinger	3
7	Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations 2023 ·JTO Clinical and Research Reports ·Sai‐Hong Ignatius Ou, Huamao Mark Lin, Jin‐Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Danny Nguyen, Joel W. Neal	25
8	Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC 2023 ·Journal of Thoracic Oncology ·Sai‐Hong Ignatius Ou, Jin‐Liern Hong, Petros Christopoulos, Huamao Mark Lin, Sylvie Vincent, Eric N. Churchill, Junpei Soeda, Daniel Kazdal, Albrecht Stenzinger, Michael Thomas	27
9	P2.27-03 Perception of Benefits and Risks of Treatments in Patients with Metastatic NSCLC with EGFRex20ins 2023 ·Journal of Thoracic Oncology ·(unknown), Elizabeth Curran, (unknown), M. Venkatraman, Huamao Mark Lin, Simon S. Ang, Farrah Pompilus, Jennifer A. Whitty, Jun Zhang, Tarek Mekhail	0
10	EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States 2022 ·JTO Clinical and Research Reports ·Huamao Mark Lin, Yu Yin, (unknown), (unknown), Sai‐Hong Ignatius Ou	17
11	Real-world ALK Testing Trends in Patients With Advanced Non–Small-Cell Lung Cancer in the United States 2022 ·Clinical Lung Cancer ·Huamao Mark Lin, (unknown), Yu Yin, Huifeng Niu, Eileen A. Curran, Christine M. Lovly, Michael Humphries	8
12	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) 2021 ·Lung Cancer ·M.R. García Campelo, Huamao Mark Lin, Yanyan Zhu, M. Pérol, Mohammad Jahanzeb, Sanjay Popat, Pingkuan Zhang, D. Ross Camidge	12
13	Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer 2020 ·Clinical Lung Cancer ·Mohammad Jahanzeb, Huamao Mark Lin, Xiaoyun Pan, Yu Yin, Pia Baumann, Corey J. Langer	47
14	Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study 2019 ·Journal of Medical Economics ·Ariane K. Kawata, William R. Lenderking, (unknown), David Kerstein, (unknown), Hui Huang, Pingkuan Zhang, Huamao Mark Lin	9
15	Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis 2018 ·Amyloid ·Parameswaran Hari, Huamao Mark Lin, Carl V. Asche, Jinma Ren, Candice Yong, Katarina Luptakova, Douglas V. Faller, Vaishali Sanchorawala	16
16	262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study 2017 ·Journal of Investigative Dermatology ·(unknown), Sean Whittaker, Steve Horwitz, Madeleine Duvic, Reinhard Dummer, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, (unknown), Maria Corinna Palanca-Wessels, Erin Zagadailov, William L. Trepicchio, Huamao Mark Lin, Melissa H. Little, H. Miles Prince	1
17	Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC) 2016 ·Annals of Oncology ·David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, Lawrence I. Karsh, Bryan A. Mehlhaff, Christopher Pieczonka, James L. Bailen, David B. MacLean, Serap Sankoh, Hélène M. Faessel, Huamao Mark Lin, Neal D. Shore	7
18	Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life 2015 ·Supportive Care in Cancer ·Rachid Baz, Huamao Mark Lin, (unknown), R. Donald Harvey, (unknown), Katy Gallop, Paul Swinburn, Jacob P. Laubach, (unknown), Paul G. Richardson	48
19	STAT-1 is activated by IL-4 and IL-13 in multiple cell types 2004 ·Molecular Immunology ·(unknown), Huamao Mark Lin, Samuel J. Goldman, Michiko Kobayashi	47
20	The involvement of the proto-oncogene p120 c-Cbl and ZAP-70 in CD2-mediated T cell activation 2001 ·International Immunology ·Huamao Mark Lin, Maria Paola Martelli, Barbara E. Bierer	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact